Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
UCB SA (DE:UNC)
FRANKFURT:UNC
UCB SA (UNC) Stock Price & Analysis
8 Followers
UNC Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€65.68 - €120.85
Previous Close€120.55
Volume70.00
Average Volume (3M)183.00
Market Cap
€22.70B
Enterprise Value€24.46B
Total Cash (Recent Filing)€1.14B
Total Debt (Recent Filing)€2.90B
Price to Earnings (P/E)N/A
Beta0.27
Next Earnings
Jul 25, 2024EPS Estimate
€1.34Last Dividend Ex-Date
Apr 28, 2023Dividend Yield0.78%
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume219
30 Day Avg. Volume183
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€124.70Price Target Upside3.44% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
UCB SA News
UNC FAQ
What was UCB SA’s price range in the past 12 months?
UCB SA lowest stock price was €65.68 and its highest was €120.85 in the past 12 months.
What is UCB SA’s market cap?
Currently, no data Available
When is UCB SA’s upcoming earnings report date?
UCB SA’s upcoming earnings report date is Jul 25, 2024 which is in 84 days.
How were UCB SA’s earnings last quarter?
UCB SA released its earnings results on Feb 28, 2024. The company reported €1.56 earnings per share for the quarter, beating the consensus estimate of €0.22 by €1.34.
Is UCB SA overvalued?
According to Wall Street analysts UCB SA’s price is currently Undervalued.
Does UCB SA pay dividends?
UCB SA pays a Annually dividend of €0.93 which represents an annual dividend yield of 0.78%. See more information on UCB SA dividends here
What is UCB SA’s EPS estimate?
UCB SA’s EPS estimate is €1.34.
How many shares outstanding does UCB SA have?
Currently, no data Available
What happened to UCB SA’s price movement after its last earnings report?
UCB SA reported an EPS of €1.56 in its last earnings report, beating expectations of €0.22. Following the earnings report the stock price went up 3.065%.
Which hedge fund is a major shareholder of UCB SA?
Currently, no hedge funds are holding shares in DE:UNC
---
UCB SA Stock Smart Score
Not Ranked
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
37.46%
12-Months-Change
Fundamentals
Return on Equity
3.80%
Trailing 12-Months
Asset Growth
-2.07%
Trailing 12-Months
Company Description
UCB SA
UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, both of which have lost patent protection. The firm's key products are Cimzia (immunology), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), Briviact (epilepsy), Evenity (osteoporosis), and Nayzilam (cluster seizures).
---
UNC Stock 12 Months Forecast
Average Price Target
€124.70
▲(3.44% Upside)
Technical Analysis
Best Analysts Covering UNC
1 Year
1 Year Success Rate
13/17 ratings generated profit
1 Year Average Return
+23.06%
reiterated a buy rating 16 days ago
Copying Charles Pitman CFA's trades and holding each position for 1 Year would result in 76.47% of your transactions generating a profit, with an average return of +23.06% per trade.
---